In the RADAR study , 85 antiretroviral-nave HIV-infected patients were randomized to receive either raltegravir ( RAL ) ( n = 42 ) or tenofovir/emtricitabine ( TDF/FTC ) ( n = 43 ) , each with ritonavir-boosted darunavir ( DRV/r ) .